Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 806-814

  Crespo, Marta ^a   Yelamos, J ^a   Redondo, D ^a   Muntasell, A ^a   Perez Saez M J ^a   Lopez Montanes M ^b   Garcia C ^c   Torio, A ^d   Mir, M ^a   Hernandez J J ^c   Lopez Botet M ^a,b   Pascual, J ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c Catalunya Reference Laboratory   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Alloantibody; clinical research practice; histocompatibility; immunosuppressive regimens; kidney transplantation nephrology; natural killer (NK) cells NK receptors; rejection: antibody mediated (ABMR); translational research science

Indexed keywords

DONOR SPECIFIC HLA ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; HLA ANTIGEN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SENSITIZATION; ALLOTRANSPLANTATION; CYTOLOGY; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; AUTOANTIBODIES; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84923293168     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13010     Document Type: Article

References (30)

1. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
2. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
3. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417.
4. Pascual J, Pérez-Sáez MJ, Mir M, Crespo M., Chronic renal allograft injury: Early detection, accurate diagnosis and management. Transplant Rev (Orlando) 2012; 26: 280-290.
5. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
6. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
7. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
8. Benichou G, Yamada Y, Aoyama A, Madsen JC., Natural killer cells in rejection and tolerance of solid organ allografts. Curr Opin Organ Transplant 2011; 16: 47-53.
9. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK-cells and alloantibody. Am J Transplant 2012; 12: 313-321.
10. Hidalgo LG, Sis B, Sellares J, et al. NK-cell transcripts and NK-cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK-cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
11. Sellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
12. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/c4d-negative and donor-specific antibody-negative/c4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 2141-2148.
13. Lanier LL., Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
14. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
15. Caligiuri MA., Human natural killer cells. Blood 2008; 112: 461-469.
16. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116: 3853-3864.
17. Muntasell A, Vilches C, Angulo A, Lopez-Botet M., Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: A different perspective of the host-pathogen interaction. Eur J Immunol 2013; 43: 1133-1141.
18. Van Bergen J, Thompson A, Haasnoot GW, et al. KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant 2011; 11: 1959-1964.
19. Tran TH, Unterrainer C, Fiedler G, et al. No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation. Am J Transplant 2013; 13: 1063-1068.
20. Colonna M, Navarro F, Bellón T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809-1818.
21. Melero I, Salmerón A, Balboa MA, et al. Tyrosine kinase-dependent activation of human NK cell functions upon stimulation through a 58-kDa surface antigen selectively expressed on discrete subsets of NK cells and T lymphocytes. J Immunol 1994; 152: 1662-1673.
22. Neudoerfl C, Mueller BJ, Blume C, et al. The peripheral NK-cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol 2013; 4: 1-14.
23. Van der Touw W, Burrell B, Lal G, Bromberg JS., NK-cells are required for costimulatory blockade induced tolerance to vascularized allografts. Transplantation 2012; 94: 575-584.
24. Farkash EA, Colvin RB., Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012; 8: 255-257.
25. Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599-3608.
26. Ortaldo JR, Mason AT, O'Shea JJ., Receptor-induced death in human natural killer cells: Involvement of CD16. J Exp Med 1995; 181: 339-344.
27. Kaiser BK, Barahmand-Pour F, Paulsene W, et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005; 174: 2878-2884.
28. Vilches C, Parham P, KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217-251.
29. Veeramani S, Wang SY, Dahle C, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118: 3347-3349.
30. Martin L, Guignier F, Bocrie O, et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 2005; 79: 1459-1461.